Evidence map›Paper›PMID 42291223›Full record

ArticleiScience2026

Sara Adnane, Yvessa Verheyden, Alessandro Cuomo, Tiziana Bonaldi, Eleonora Leucci

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara AdnaneLaboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, 3001 Leuven, Belgium.
Yvessa VerheydenLaboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, 3001 Leuven, Belgium.
Alessandro CuomoIEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139 Milan, Italy.
Tiziana BonaldiIEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139 Milan, Italy.
Eleonora LeucciLaboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, 3001 Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite remarkable advances in targeted therapies and immunotherapies, a subset of patients fails to respond due to intrinsic resistance, and the majority of those who initially benefit eventually relapse. The emergence of resistant clones under therapeutic pressure has been attributed to both genetic and/or non-genetic resistance mechanisms. Understanding the mechanisms of drug tolerance that drive persistence and resistance, as well as identifying novel biomarkers and therapeutic vulnerabilities, is therefore critically important. Many long non-coding RNAs (lncRNAs) have been implicated in DNA damage; however, their role in melanoma, a malignancy characterized by high mutational rates, remains elusive. Here, we identify the lncRNA

Indexed as

Cancer systems biologyCell biology

Identifiers

PMID42291223
PMCPMC13264319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.